Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma

Urology

Volumn 68, Issue 2, 2006, Pages 296-301

  Tripathi, Rekha T ^a   Heilbrun, Lance K ^b   Jain, Vikash ^b   Vaishampayan, Ulka N ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; EUROPEAN AMERICAN; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIVER METASTASIS; LOG RANK TEST; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PATIENT CARE; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SEX RATIO; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AFRICAN AMERICANS; AGED; CARCINOMA, RENAL CELL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33746843631     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.02.036     Document Type: Article

References (16)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 1628-1631
3. Pantuck A.J., Zisman A., and Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 166 (2001) 1611-1623
4. Vaishampayan U.N., Do H., Hussain M., et al. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 62 (2003) 1012-1017
5. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am Suppl 1 (2000) S55-S57
6. Newman L.A., Carolin K., Simon M., et al. Impact of breast carcinoma on African-American women. the Detroit experience. Cancer 91 (2001) 1834-1843
7. Cross C.K., Schultz D., Malkowicz B.S., et al. Impact of race on prostate specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of prostate. J Clin Oncol 20 (2002) 2863-2868
8. Dayal H.H., Polissar L., and Dahlberg S. Race, socioeconomic status and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst 74 (1985) 1001-1006
9. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc Series B 34 (1972) 187-220
10. Allison P.D. Survival Analysis Using the SAS System. A Practical Guide (1995), SAS Institute, Cary, NC
11. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma. early results of a randomised controlled trial. Lancet 353 (1999) 14-17
12. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
13. Rowinsky E.K., Schwartz G.H., Gollob J.A., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22 (2004) 3003-3015
14. Ratain M.J., Flaherty K.T., Stadler W.M., et al. Preliminary antitumor activity of BAY43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. (abstract). Proc Am Soc Clin Oncol 23 (2004) 381
15. Bain C., Merrouche Y., Puisieux I., et al. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 75 (1997) 283-286
16. Franzke A., Buer J., Probst-Kepper M., et al. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. Cancer Biother Radiopharm 16 (2001) 401-409